Buch, Englisch, 208 Seiten, Format (B × H): 136 mm x 216 mm, Gewicht: 261 g
Issues and Challenges
Buch, Englisch, 208 Seiten, Format (B × H): 136 mm x 216 mm, Gewicht: 261 g
Reihe: Chapman & Hall/CRC Biostatistics Series
ISBN: 978-1-4665-6149-6
Verlag: Taylor & Francis Inc
Take Your NI Trial to the Next Level
Reflecting the vast research on noninferiority (NI) designs from the past 15 years, Noninferiority Testing in Clinical Trials: Issues and Challenges explains how to choose the NI margin as a small fraction of the therapeutic effect of the active control in a clinical trial. Requiring no prior knowledge of NI testing, the book is easily accessible to both statisticians and nonstatisticians involved in drug development.
With over 20 years of experience in this area, the author introduces the basic elements of the NI trials one at a time in a logical order. He discusses issues with estimating the effect size based on historical placebo control trials of the active control. The book covers fundamental concepts related to NI trials, such as assay sensitivity, constancy assumption, discounting, and preservation. It also describes patient populations, three-arm trials, and the equivalence of three or more groups.
Zielgruppe
Statisticians and clinicians involved in the design, conduct, and analysis of noninferiority trials.
Autoren/Hrsg.
Fachgebiete
- Mathematik | Informatik Mathematik Stochastik
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Epidemiologie, Medizinische Statistik
Weitere Infos & Material
Introduction. Choice of Noninferiority Margin for the Mean Difference. Choice of Noninferiority Margin for the Mean Ratio and Hazard Ratio. Noninferiority Hypotheses with Binary Endpoints. Two Statistical Approaches for Testing the Noninferiority Hypothesis. Switching between Superiority and Noninferiority. Multiple Historical Studies and Meta-Analysis. Three Treatment Groups. Regulatory Guidances. Intention-to-Treat versus Per-Protocol. Thrombolytic Example. Issues and Challenges. Index.
